Norfloxacin Injection

This product is a broad-spectrum antibacterial drug with strong antibacterial effects on both Gram-positive and Gram-negative bacteria. There is no cross-resistance between similar drugs and antibiotics. It has strong antibacterial activity against Gram-negative bacteria, especially bacteria of the Enterobacteriaceae family, such as Escherichia coli, Shigella, Klebsiella, Proteus, Enterobacter aerogenes, Serratia, Citrobacter, etc., which are highly sensitive to this product, and the minimum inhibitory concentration is generally less than 0.5mu;g/ml. It also has an effect on Pseudomonas aeruginosa and other Pseudomonas, but requires a higher concentration, with a minimum inhibitory concentration of 4 to 32mu;g/ml; because the concentration in urine exceeds the above concentration by several to more than ten times, it is still effective for the treatment of Pseudomonas aeruginosa urinary tract infections. Among Gram-positive cocci, it is more sensitive to Staphylococcus aureus and Staphylococcus epidermidis. The minimum concentration for inhibiting 90% of bacteria is about 1-2 mu;g/ml, and the minimum concentration for inhibiting 90% of enterococci and pneumococci is about 4 mu;g/ml and 16 mu;g/ml.

The main ingredient is norfloxacin, whose chemical name is 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid

This product is a light yellow-green clear liquid.

It is suitable for respiratory tract, urinary tract and gastrointestinal tract infections caused by sensitive bacteria, such as acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, acute and chronic pyelonephritis, cystitis, typhoid fever, etc.

Intravenous drip: For adults, 0.2g is diluted in 250ml of 5% glucose injection and dripped over 1.5 to 2 hours, twice a day. For severe cases, 0.4g is diluted in 500ml of 5% glucose injection and dripped over 3 to 4 hours, twice a day. For acute infection, one course of treatment is generally 7 to 14 days, and for chronic infection, one course of treatment is 14 to 21 days, or follow the doctor's advice.

A small number of patients may have gastrointestinal symptoms such as abdominal discomfort, nausea, and vomiting. Some patients may have symptoms such as headache, dizziness, rash, and itching. Occasionally, serum alanine aminotransferase levels may increase, and the symptoms may disappear after stopping the drug.

1. Patients who are allergic to quinolones and this product are contraindicated. 2. Patients with diabetes are contraindicated.

1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the liver clearance of theophylline, a prolonged blood elimination half-life (t1/2b), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, theophylline blood drug concentration should be measured and the dose adjusted when used in combination. 3 Cyclosporine combined with this product can increase its blood drug concentration. Cyclosporine blood concentration must be monitored and the dose adjusted. 4 This product can enhance the anticoagulant effect of the latter when used with the anticoagulant warfarin. When used in combination, the patient's prothrombin time should be closely monitored. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6 This product has an antagonistic effect with nitrofurantoin and is not recommended for combined use. 7 Multivitamins, or other preparations containing iron or zinc ions, and antacids containing aluminum or magnesium can reduce the absorption of this product. It is recommended to avoid co-administration. If it cannot be avoided, take it 2 hours before or 6 hours after taking this product. 8 Didanosine (DDI) can reduce the oral absorption of this product. Because its preparation contains aluminum and magnesium, it can chelate with fluoroquinolones, so it is not suitable for co-administration. 9 This product interferes with the metabolism of caffeine, resulting in reduced caffeine clearance, prolonged blood elimination half-life (t1/2b), and possible central nervous system toxicity.

Keep away from light and store in a sealed container.

2ml:0.1g

Dalian Huali Jingang Pharmaceutical Co., Ltd.

• Founded in:

  1992-12-03

• Address:

  No. 8 Chengen Street, Jinzhou District, Dalian City, Liaoning Province

• Tax NO.:

  912102136048258717

• Registered Funds:

  8.88 million yuan

• Website:

  Log in to view

• Email:

  Log in to view